IL2 and rheumatoid arthritis: Induction therapy—often involving a biologic agent like a lymphocyte-depleting agent or an interleukin-2 receptor antagonist (IL-2 RA)—is applied to modulate T-cell responses during antigen presentation at the time of transplantation, as oral maintenance immunosuppressants exhibit a delayed effect on immune cells (1).